Related Experiment Video

Updated: Apr 30, 2026

A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery
07:20

A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery

Published on: February 28, 2020

11.0K

Platelet factor 4 inhibits IL-17/Stat3 pathway via upregulation of SOCS3 expression in melanoma

Shanshan Fang1, Bo Liu, Qiushi Sun

  • 1Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Jinzhou Road 136#, Xiangyang, 441053, Hubei, China.

Inflammation
|May 7, 2014
PubMed

Insights

Platelet factor 4 (PF4) inhibits melanoma tumor growth by downregulating the IL-17/Stat3 pathway. This immune modulation is mediated by increased SOCS3 expression, offering potential therapeutic strategies for cancer.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Platelet factor 4 (PF4) is a CXC chemokine involved in inflammation and immune responses.
  • Its role in tumor immunity is not well understood, necessitating further investigation.
  • Previous studies suggest PF4 influences T helper 17 (Th17) and regulatory T cell development.

Purpose of the Study:

  • To investigate the immunoregulatory role of PF4 in a murine melanoma model.
  • To elucidate the molecular mechanisms by which PF4 affects tumor growth and immune cell infiltration.

Main Methods:

  • Inoculation of wild-type mice with B16 melanoma cells and treatment with PF4.
  • Assessment of tumor growth, γδ cell infiltration, and expression of key cytokines (IL-17, IL-6) and signaling proteins (p-Stat3).
  • In vitro studies using cell transfection with SOCS3 siRNA to examine pathway involvement.

Main Results:

  • PF4 treatment inhibited B16 tumor growth and reduced γδ cell infiltration.
  • PF4 significantly decreased the expression of IL-17, IL-6, and p-Stat3.
  • Recombinant IL-17 reversed the tumor suppressive effects of PF4, and SOCS3 upregulation was identified as a key mechanism.

Conclusions:

  • PF4 suppresses melanoma tumor growth in mice.
  • The mechanism involves the inhibition of the IL-17/Stat3 signaling pathway through SOCS3 upregulation.
  • PF4 demonstrates potential as a therapeutic agent in melanoma treatment.

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.9K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

915

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K